Troels Jordansen, CEO
Oss, The Netherlands
Glycostem has developed a platform technology for the expansion and differentiation of allogeneic hematopoietic stem and progenitor cells derived from umbilical cord blood. This enables off-the-shelf, safe and low production cost products. Glycostem’s platform technology enables a closed system cell culture process for the expansion of CD34+ hematopoietic stem and progenitor cells, and further differentiation into fully functional immune cells, i.e. Natural Killer (NK) cells. Glycostem has treated 10 elderly and fragile AML patients in a Phase I setting with an excellent safety profile and strong indication of clinical efficacy. Year one survival data showed 80% compared to the general AML population data showing 35%. A GMP license was received for the company’s own manufacturing unit in 2019, and pivotal trials in acute myeloid leukemia (AML) and multiple myeloma (MM) will commence 2H 2020.

By using this website you agree to accept our Privacy Policy and Terms & Conditions